1. Park WD, Grande JP, Ninova D, Nath KA, Platt JL, Gloor JM, Stegall MD. Accommodation in ABO-incompatible kidney allografts, a novel mechanism of self-protection against antibody-mediated injury.
Am J Transplant 3:2003;952–960.
2. Tobian AA, Shirey RS, Montgomery RA, Cai W, Haas M, Ness PM, King KE. ABO antibody titer and risk of antibody-mediated rejection in ABO-incompatible renal transplantation.
Am J Transplant 10:2010;1247–1253.
3. Alexandre GP, Squifflet JP, De Bruyere M, Latinne D, Reding R, Gianello P, Carlier M, Pirson Y. Present experiences in a series of 26 ABO-incompatible living donor renal allografts.
Transplant Proc 19:1987;4538–4542.
4. Takahashi K, Saito K. ABO-incompatible kidney transplantation.
Transplant Rev 27:2013;1–8.
5. Ishida H, Miyamoto N, Shirakawa H, Shimizu T, Tokumoto T, Ishikawa N, Shimmura H, Setoguchi K, Toki D, Iida S, Teraoka S, Takahashi K, Toma H, Yamaguchi Y, Tanabe K. Evaluation of immunosuppressive regimens in ABO-incompatible living kidney transplantation-single center analysis.
Am J Transplant 7:2007;825–831.
6. Ichimaru N, Takahara S. Japan׳s experience with living-donor kidney transplantation across ABO barriers.
Nat Clin Pract Nephrol 4:2008;682–692.
7. Tyden G, Kumlien G, Fehrman I. Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab.
Transplantation 76:2003;730–731.
8. Fuchinoue S, Ishii Y, Sawada T, Murakami T, Iwadoh K, Sannomiya A, Koyama I, Kubota K, Tojimbara T, Nakajima I, Teraoka S. The 5-year outcome of ABO-incompatible kidney transplantation with rituximab induction.
Transplantation 91:2011;853–857.
9. Stegall MD, Dean PG, Gloor JM. ABO-incompatible kidney transplantation.
Transplantation 78:2004;635–640.
10. Tyden G, Kumlien G, Genberg H, Sandberg J, Lundgren T, Fehrman I. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab.
Am J Transplant 5:2005;145–148.
11. Montgomery JR, Berger JC, Warren DS, James NT, Montgomery RA, Segev DL. Outcomes of ABO-incompatible kidney transplantation in the United States.
Transplantation 93:2012;603–609.
12. http://nhsbtmediaservices.blob.core.windows.net/organ-donation-assets/pdfs/activity_report_2014_15.pdf.
13. Kong JM, Ahn J, Park JB, Chung BH, Yang J, Kim JK, Huh KH, Kim JM. ABO incompatible living donor kidney transplantation in Korea: highly uniform protocols and good medium-term outcome.
Clin Transplant 27:2013;875–881.
14. http://www.kotry.org/ko.
15. Mond JJ, Lees A, Snapper CM. T cell-independent antigens type 2.
Annu Rev Immunol 13:1995;655–692.
16. Economidou J, Hughes-Jones NC, Gardner B. Quantitative measurements concerning A and B antigen sites.
Vox Sang 12:1967;321–328.
17. Thielke J, Kaplan B, Benedetti E. The role of ABO-incompatible living donors in kidney transplantation: state of the art.
Semin Nephrol 27:2007;408–413.
18. Fehr T, Stussi G. ABO-incompatible kidney transplantation.
Curr Opin Organ Transplant 17:2012;376–385.
19. Conway J, Manlhiot C, Allain-Rooney T, McCrindle BW, Lau W, Dipchand AI. Development of donor-specific isohemagglutinins following pediatric ABO-incompatible heart transplantation.
Am J Transplant 12:2012;888–895.
20. Irei T, Ohdan H, Zhou W, Ishiyama K, Tanaka Y, Ide K, Asahara T. The persistent elimination of B cells responding to blood group A carbohydrates by synthetic group A carbohydrates and B-1 cell differentiation blockade: novel concept in preventing antibody-mediated rejection in ABO-incompatible transplantation.
Blood 110:2007;4567–4575.
21. Tazawa H, Irei T, Tanaka Y, Igarashi Y, Tashiro H, Ohdan H. Blockade of invariant TCR-CD1d interaction specifically inhibits antibody production against blood group A carbohydrates.
Blood 122:2013;2582–2590.
22. Toki D, Ishida H, Setoguchi K, Shimizu T, Omoto K, Shirakawa H, Iida S, Horita S, Furusawa M, Ishizuka T, Yamaguchi Y, Tanabe K. Acute antibody-mediated rejection in living ABO-incompatible kidney transplantation: long-term impact and risk factors.
Am J Transplant 9:2009;567–577.
23. Kobayashi T, Saito K. A series of surveys on assay for anti-A/B antibody by Japanese ABO-incompatible Transplantation Committee.
Xenotransplantation 13:2006;136–140.
24. Stussi G, Huggel K, Lutz HU, Schanz U, Rieben R, Seebach JD. Isotype-specific detection of ABO blood group antibodies using a novel flow cytometric method.
Br J Haematol 130:2005;954–963.
25. Lindberg L, Johansson SM, Liu J, Grufman P, Holgersson J. Is there a clinical need for a diagnostic test allowing detection of chain type-specific anti-A and anti-B?
Transfusion 51:2011;494–503.
26. Kumlien G, Wilpert J, Safwenberg J, Tyden G. Comparing the tube and gel techniques for ABO antibody titration, as performed in three European centers.
Transplantation 84:2007;S17–S19.
27. Tanabe K. Interinstitutional variation in the measurement of anti-A/B antibodies: the Japanese ABO-Incompatible Transplantation Committee survey.
Transplantation 84:2007;S13–S16.
28. Takahashi K. Recent findings in ABO-incompatible kidney transplantation: classification and therapeutic strategy for acute antibody-mediated rejection due to ABO-blood-group-related antigens during the critical period preceding the establishment of accommodation.
Clin Exp Nephrol 11:2007;128–141.
29. Fidler ME, Gloor JM, Lager DJ, Larson TS, Griffin MD, Textor SC, Schwab TR, Prieto M, Nyberg SL, Ishitani MB, Grande JP, Kay PA, Stegall MD. Histologic findings of antibody-mediated rejection in ABO blood-group-incompatible living-donor kidney transplantation.
Am J Transplant 4:2004;101–107.
30. Gloor JM, Lager DJ, Fidler ME, Grande JP, Moore SB, Winters JL, Kremers WK, Stegall MD. A comparison of splenectomy versus intensive posttransplant antidonor blood group antibody monitoring without splenectomy in ABO-incompatible kidney transplantation.
Transplantation 80:2005;1572–1577.
31. Racusen LC, Haas M. Antibody-mediated rejection in renal allografts: lessons from pathology.
Clin J Am Soc Nephrol 1:2006;415–420.
32. Haas M, Segev DL, Racusen LC, Bagnasco SM, Locke JE, Warren DS, Simpkins CE, Lepley D, King KE, Kraus ES, Montgomery RA. C4d deposition without rejection correlates with reduced early scarring in ABO-incompatible renal allografts.
J Am Soc Nephrol 20:2009;197–204.
33. Setoguchi K, Ishida H, Shimmura H, Shimizu T, Shirakawa H, Omoto K, Toki D, Iida S, Setoguchi S, Tokumoto T, Horita S, Nakayama H, Yamaguchi Y, Tanabe K. Analysis of renal transplant protocol biopsies in ABO-incompatible kidney transplantation.
Am J Transplant 8:2008;86–94.
34. Haas M, Rahman MH, Racusen LC, Kraus ES, Bagnasco SM, Segev DL, Simpkins CE, Warren DS, King KE, Zachary AA, Montgomery RA. C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: correlation with histologic findings.
Am J Transplant 6:2006;1829–1840.
35. Takahashi K, Saito K, Nakagawa Y, Tasaki M, Hara N, Imai N. Mechanism of acute antibody-mediated rejection in ABO-incompatible kidney transplantation: which anti-A/anti-B antibodies are responsible, natural or
de novo?
Transplantation 89:2010;635–637.
36. Magee CC. Transplantation across previously incompatible immunological barriers.
Transpl Int 19:2006;87–97.
37. Gloor JM, Stegall MD. ABO incompatible kidney transplantation.
Curr Opin Nephrol Hypertens 16:2007;529–534.
38. Williams JM, Holzknecht ZE, Plummer TB, Lin SS, Brunn GJ, Platt JL. Acute vascular rejection and accommodation: divergent outcomes of the humoral response to organ transplantation.
Transplantation 78:2004;1471–1478.
39. Iwasaki K, Miwa Y, Haneda M, Uchida K, Nakao A, Kobayashi T. Significance of HLA class I antibody-induced antioxidant gene expression for endothelial cell protection against complement attack.
Biochem Biophys Res Commun 391:2010;1210–1215.
40. Chen Song S, Zhong S, Xiang Y, Li JH, Guo H, Wang WY, Xiong YL, Li XC, Chen Shi S, Chen XP, Chen G. Complement inhibition enables renal allograft accommodation and long-term engraftment in presensitized nonhuman primates.
Am J Transplant 11:2011;2057–2066.
41. Iwasaki K, Miwa Y, Ogawa H, Yazaki S, Iwamoto M, Furusawa T, Onishi A, Kuzuya T, Haneda M, Watarai Y, Uchida K, Kobayashi T. Comparative study on signal transduction in endothelial cells after anti-a/b and human leukocyte antigen antibody reaction: implication of accommodation.
Transplantation 93:2012;390–397.
42. West LJ. Targeting antibody-mediated rejection in the setting of ABO-incompatible infant heart transplantation: graft accommodation vs. B cell tolerance.
Curr Drug Targets Cardiovas Haematol Disord 5:2005;223–232.
43. Smith RN, Kawai T, Boskovic S, Nadazdin O, Sachs DH, Cosimi AB, Colvin RB. Four stages and lack of stable accommodation in chronic alloantibody-mediated renal allograft rejection in Cynomolgus monkeys.
Am J Transplant 8:2008;1662–1672.
44. Tobian AA, Shirey RS, Montgomery RA, Tisch DJ, Ness PM, King KE. Therapeutic plasma exchange reduces ABO titers to permit ABO-incompatible renal transplantation.
Transfusion 49:2009;1248–1254.
45. Higgins R, Lowe D, Hathaway M, Lam FT, Kashi H, Tan LC, Imray C, Fletcher S, Chen K, Krishnan N, Hamer R, Zehnder D, Briggs D. Double filtration plasmapheresis in antibody-incompatible kidney transplantation.
Ther Apher Dial 14:2010;392–399.
46. Tyden G, Kumlien G, Efvergren M. Present techniques for antibody removal.
Transplantation 84:2007;S27–S29.
47. Tobian AA, Shirey RS, Montgomery RA, Ness PM, King KE. The critical role of plasmapheresis in ABO-incompatible renal transplantation.
Transfusion 48:2008;2453–2460.
48. Montgomery RA. Renal transplantation across HLA and ABO antibody barriers: integrating paired donation into desensitization protocols.
Am J Transplant 10:2010;449–457.
49. Segev DL, Simpkins CE, Warren DS, King KE, Shirey RS, Maley WR, Melancon JK, Cooper M, Kozlowski T, Montgomery RA. ABO incompatible high-titer renal transplantation without splenectomy or anti-CD20 treatment.
Am J Transplant 5:2005;2570–2575.
50. Geyer M, Donauer J, Pisarski P, Drognitz O, Schulz-Huotari C, Wisniewski U, Gropp A, Gobel H, Gerke P, Teschner S, Walz G, Wilpert J. Preemptive postoperative antigen-specific immunoadsorption in ABO-incompatible kidney transplantation: necessary or not?
Transplantation 84:2007;S40–S43.
51. Sawada T, Fuchinoue S, Teraoka S. Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis.
Transplantation 74:2002;1207–1210.
52. Clatworthy MR. Targeting B cells and antibody in transplantation.
Am J Transplant 11:2011;1359–1367.
53. Genberg H, Kumlien G, Wennberg L, Berg U, Tyden G. ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up.
Transplantation 85:2008;1745–1754.
54. Egawa H, Ohmori K, Haga H, Tsuji H, Yurugi K, Miyagawa-Hayashino A, Oike F, Fukuda A, Yoshizawa J, Takada Y, Tanaka K, Maekawa T, Ozawa K, Uemoto S. B-cell surface marker analysis for improvement of rituximab prophylaxis in ABO-incompatible adult living donor liver transplantation.
Liver Transpl 13:2007;579–588.
55. Chikaraishi T, Sasaki H, Tsutsumi H, Miyano S, Nakazawa R, Nakano T, Kitajima K, Kudo H, Takahashi T, Sato Y, Kimura K. ABO blood type incompatible kidney transplantation without splenectomy prepared with plasma exchange and rituximab.
Transplant Proc 40:2008;3445–3447.
56. Flint SM, Walker RG, Hogan C, Haeusler MN, Robertson A, Francis DM, Millar R, Finlay M, Landgren A, Cohney SJ. Successful ABO-incompatible kidney transplantation with antibody removal and standard immunosuppression.
Am J Transplant 11:2011;1016–1024.
57. Ashimine S, Watarai Y, Yamamoto T, Hiramitsu T, Tsujita M, Nanmoku K, Goto N, Takeda A, Katayama A, Uchida K, Kobayashi T. Neither pretransplant rituximab nor splenectomy affects de novo HLA antibody production after renal transplantation.
Kidney Int 85:2014;425–430.
58. Toki D, Ishida H, Horita S, Setoguchi K, Yamaguchi Y, Tanabe K. Impact of low-dose rituximab on splenic B cells in ABO-incompatible renal transplant recipients.
Transpl Int 22:2009;447–454.
59. Jordan SC, Toyoda M, Kahwaji J, Vo AA. Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients.
Am J Transplant 11:2011;196–202.
60. Tanabe K. Japanese experience of ABO-incompatible living kidney transplantation.
Transplantation 84:2007;S4–S7.
61. Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
Clin Transplant 22:2008;1–15.
62. Oettl T, Zuliani E, Gaspert A, Hopfer H, Dickenmann M, Fehr T. Late steroid withdrawal after ABO blood group-incompatible living donor kidney transplantation: high rate of mild cellular rejection.
Transplantation 89:2010;702–706.
63. Geyer M, Fischer KG, Drognitz O, Walz G, Pisarski P, Wilpert J. ABO-incompatible kidney transplantation with antigen-specific immunoadsorption and rituximab – insights and uncertainties.
Contrib Nephrol 162:2009;47–60.
64. Takahashi K, Saito K, Takahara S, Okuyama A, Tanabe K, Toma H, Uchida K, Hasegawa A, Yoshimura N, Kamiryo Y. Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan.
Am J Transplant 4:2004;1089–1096.
65. Montgomery RA, Locke JE, King KE, Segev DL, Warren DS, Kraus ES, Cooper M, Simpkins CE, Singer AL, Stewart ZA, Melancon JK, Ratner L, Zachary AA, Haas M. ABO incompatible renal transplantation: a paradigm ready for broad implementation.
Transplantation 87:2009;1246–1255.
66. Venetz JP, Pascual M. New treatments for acute humoral rejection of kidney allografts.
Expert Opin Investig Drugs 16:2007;625–633.
67. Galliford J, Charif R, Chan KK, Loucaidou M, Cairns T, Cook HT, Dorling A, Hakim N, McLean A, Papalois V, Malde R, Regan F, Redman M, Warrens A.N., Taube D.. ABO incompatible living renal transplantation with a steroid sparing protocol.
Transplantation 86:2008;901–906.
68. Montgomery RA, Zachary AA, Racusen LC, Leffell MS, King KE, Burdick J, Maley WR, Ratner LE. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients.
Transplantation 70:2000;887–895.
69. Kaplan B, Gangemi A, Thielke J, Oberholzer J, Sankary H, Benedetti E. Successful rescue of refractory, severe antibody mediated rejection with splenectomy.
Transplantation 83:2007;99–100.
70. Garrett HE Jr, Groshart K, Duvall-Seaman D, Combs D, Suggs R. Treatment of humoral rejection with rituximab.
Ann Thorac Surg 74:2002;1240–1242.
71. Sarwal M, Chua MS, Kambham N, Hsieh SC, Satterwhite T, Masek M, Salvatierra O Jr. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling.
N Engl J Med 349:2003;125–138.
72. Everly JJ, Walsh RC, Alloway RR, Woodle ES. Proteasome inhibition for antibody-mediated rejection.
Curr Opin Organ Transplant 14:2009;662–666.
73. Wahrmann M, Haidinger M, Kormoczi GF, Weichhart T, Saemann MD, Geyeregger R, Kikic Z, Prikoszovich T, Drach J, Bohmig GA. Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates.
Transplantation 89:2010;1385–1390.
74. Westphal S, Hansson S, Stelin G, Holgersson J, Mjornstedt L, Friman S. Successful treatment of severe ABO antibody-mediated rejection using bortezomib: a case report.
Transplant Proc 45:2013;1213–1215.
75. Boothpur R, Torrence S, Brennan DC. Bortezomib does not reduce ABO-isoagglutinin titers and may not be useful for ABO-incompatible transplant desensitization. Clin Transplant 23:2009;491–493.
76. Crew RJ, Ratner LE. ABO-incompatible kidney transplantation: current practice and the decade ahead.
Curr Opin Organ Transplant 15:2010;526–530.
77. Stewart ZA, Collins TE, Schlueter AJ, Raife TI, Holanda DG, Nair R, Reed AI, Thomas CP. Case report: eculizumab rescue of severe accelerated antibody-mediated rejection after ABO-incompatible kidney transplant.
Transplant Proc 44:2012;3033–3036.
78. Oettl T, Halter J, Bachmann A, Guerke L, Infanti L, Oertli D, Mihatsch M, Gratwohl A, Steiger J, Dickenmann M. ABO blood group-incompatible living donor kidney transplantation: a prospective, single-centre analysis including serial protocol biopsies.
Nephrol Dial Transplant 24:2009;298–303.
79. Wilpert J, Fischer KG, Pisarski P, Wiech T, Daskalakis M, Ziegler A, Neumann-Haefelin E, Drognitz O, Emmerich F, Walz G, Geyer M. Long-term outcome of ABO-incompatible living donor kidney transplantation based on antigen-specific desensitization. An observational comparative analysis.
Nephrol Dial Transplant 25:2010;3778–3786.
80. Tyden G, Kumlien G, Berg UB. ABO-incompatible kidney transplantation in children.
Pediatr Transplant 15:2011;502–504.
81. Habicht A, Broker V, Blume C, Lorenzen J, Schiffer M, Richter N, Klempnauer J, Haller H, Lehner F, Schwarz A. Increase of infectious complications in ABO-incompatible kidney transplant recipients – a single centre experience.
Nephrol Dial Transplant 26:2011;4124–4131.
82. Lipshutz GS, McGuire S, Zhu Q, Ziman A, Davis R, Goldfinger D, Reed EF, Wilkinson AH, Danovitch GM, Pham PT. ABO blood type-incompatible kidney transplantation and access to organs.
Arch Surg 146:2011;453–458.
83. Morath C, Becker LE, Leo A, Beimler J, Klein K, Seckinger J, Kihm LP, Schemmer P, Macher-Goeppinger S, Wahrmann M, Bohmig GA, Opelz G, Susal C, Zeier M, Schwenger V. ABO-incompatible kidney transplantation enabled by non-antigen-specific immunoadsorption.
Transplantation 93:2012;827–834.
84. Opelz G, Morath C, Susal C, Tran TH, Zeier M, Dohler B. Three-year outcomes following 1420 ABO-incompatible living-donor kidney transplants performed after ABO antibody reduction: results from 101 centers.
Transplantation 99:2015;400–404.
85. Ushigome H, Okamoto M, Koshino K, Nobori S, Okajima H, Masuzawa N, Urasaki K, Yoshimura N. Findings of graft biopsy specimens within 90 days after ABO blood group incompatible living donor kidney transplantation compared with ABO-identical and non-identical transplantation.
Clin Transplant 24(Suppl 22):2010;S16–S21.
86. Gloor JM, Cosio FG, Rea DJ, Wadei HM, Winters JL, Moore SB, DeGoey SR, Lager DJ, Grande JP, Stegall MD. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation.
Am J Transplant 6:2006;1841–1847.
87. Kohei N, Hirai T, Omoto K, Ishida H, Tanabe K. Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period.
Am J Transplant 12:2012;469–476.
88. Grim SA, Pham T, Thielke J, Sankary H, Oberholzer J, Benedetti E, Clark NM. Infectious complications associated with the use of rituximab for ABO-incompatible and positive cross-match renal transplant recipients.
Clin Transplant 21:2007;628–632.
89. Kamar N, Milioto O, Puissant-Lubrano B, Esposito L, Pierre MC, Mohamed AO, Lavayssiere L, Cointault O, Ribes D, Cardeau I, Nogier MB, Durand D, Abbal M, Blancher A, Rostaing L. Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients.
Am J Transplant 10:2010;89–98.
90. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States.
Am J Transplant 4:2004;905–913.
91. Yamamoto T, Kawaguchi T, Watarai Y, Tujita M, Hiramitsu T, Nanmoku K, Goto N, Katayama A, Kobayashi T, Uchida K. Potent immunosuppression for ABO-incompatible renal transplantation may not be a risk factor for malignancy.
Transplant Proc 44:2012;210–213.
92. Hall EC, Engels EA, Montgomery RA, Segev DL. Cancer risk after ABO-incompatible living-donor kidney transplantation.
Transplantation 96:2013;476–479.
93. Loubeau PR, Loubeau JM, Jantzen R. The economics of kidney transplantation versus hemodialysis.
Prog Transplant 11:2001;291–297.
94. Haller M, Gutjahr G, Kramar R, Harnoncourt F, Oberbauer R. Cost-effectiveness analysis of renal replacement therapy in Austria.
Nephrol Dial Transplant 26:2011;2988–2995.
95. Schwartz J, Stegall MD, Kremers WK, Gloor J. Complications, resource utilization, and cost of ABO-incompatible living donor kidney transplantation.
Transplantation 82:2006;155–163.
96. Tyden G. Cost effectiveness of ABO-incompatible kidney transplantations.
Transplantation 82:2006;166–167.
97. Lawrence C, Galliford JW, Willicombe MK, McLean AG, Lesabe M, Rowan F, Papalois V, Regan F, Taube D. Antibody removal before ABO-incompatible renal transplantation: how much plasma exchange is therapeutic?
Transplantation 92:2011;1129–1133.
98. Chung BH, Lee JY, Kang SH, Sun IO, Choi SR, Park HS, Kim JI, Moon IS, Choi BS, Park CW, Kim YS, Yang CW. Comparison of clinical outcome between high and low baseline anti-ABO antibody titers in ABO-incompatible kidney transplantation.
Ren Fail 33:2011;150–158.
99. Shimmura H, Tanabe K, Ishikawa N, Tokumoto T, Takahashi K, Toma H. Role of anti-A/B antibody titers in results of ABO-incompatible kidney transplantation.
Transplantation 70:2000;1331–1335.
100. Gloor JM, Lager DJ, Moore SB, Pineda AA, Fidler ME, Larson TS, Grande JP, Schwab TR, Griffin MD, Prieto M, Nyberg SL, Velosa JA, Textor SC, Platt JL, Stegall MD. ABO-incompatible kidney transplantation using both A2 and non-A2 living donors.
Transplantation 75:2003;971–977.
101. Kayler LK, Farber JL, Colombe B, LaCava D, Friedewald JJ, Ratner LE. Characterization of rejection episodes in patients following positive crossmatch and ABO-incompatible live donor renal transplantation.
Transpl Int 19:2006;128–139.
102. Ishida H, Kondo T, Shimizu T, Nozaki T, Tanabe K. Postoperative rebound of antiblood type antibodies and antibody-mediated rejection after ABO-incompatible living-related kidney transplantation.
Transpl Int 28:2015;286–296.
103. Chuang JP, Hung CJ, Chang SS, Chou TC, Lee PC. Does immunosuppressive pharmacotherapy affect isoagglutinin titers?
Transplant Proc 40:2008;2685–2687.
104. Kato Y, Tojimbara T, Iwadoh K, Koyama I, Nanmoku K, Kai K, Sannomiya A, Nakajima I, Fuchinoue S, Teraoka S. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
Int Immunopharmacol 6:2006;1984–1992.
105. Gloor J, Matas AJ. Steroid-free maintenance immunosuppression and ABO-incompatible transplantation.
Transplantation 89:2010;648–649.